PRODUCTS
Vaccines Pipeline
Vaccines Pipeline
We are committed to developing a vaccines’ pipeline against the most worrisome bacteria because of their capacity of resistance to all or almost available antibiotics
PRODUCTS
K-Vax
Active principle: IInactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Klebsiella pneumoniae.
Stage: Pre-clinical development
Indication: Raise active immunity against 100% of circulating strains of K. pneumoniae and A. baumannii, in the population in hospitals or the community at risk of developing infections by K. pneumoniae and A. baumannii.
Highlights: Multivalent vaccine candidate of Vaxdyn’s technological platform. First proof of principle in humans expected in 2025. Product powered by the global accelerator CARB-X.
P-Vax
Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Pseudomonas aeruginosa.
Stage: Pre-clinical development
Indication: Raise active immunity against 100% of circulating strains of P. aeruginosa and A. baumannii, in the population in hospitals or the community at risk of developing infections by P. aeruginosa and A. baumannii.
AcinetoVax
Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine.
Stage: Pre-clinical development
Indication: Raise active immunity against 100% of circulating strains of Acinetobacter baumannii, in the population in hospitals or the community at risk of developing infections by A. baumannii.
EcoVax
Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Extraintestinal Pathogenic Escherichia coli (ExPEC).
Stage: Lead Optimization.
Indication: Raise active immunity against 100% of circulating strains of ExPEC and A. baumannii, in the community at risk of developing infections by ExPEC and A. baumannii.
AppeVax
Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Actinobacillus pleuropneumoniae.
Stage: Lead Optimization.
Indication: A vaccine for prevention of porcine pleuropneumonia caused by the pig respiratory pathogens A. pleuropneumoanie.
CONTACT
Vaxdyn
Supported by CARB-X
Member of ASEBIO, Spanish Industry Association
Member of BEAM Alliance, Biotech companies from Europe innovating in Anti-Microbial resistance research
